News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Completes Move into New Corporate Headquarters

SOUTHBOROUGH, MA – July 13, 2015Veristat, a full service Clinical Research Organization (CRO), announced today that it has completed the move of its corporate headquarters to Southborough, Massachusetts. As previously announced, the move was driven by Veristat’s rapid growth in response to the increased demand for full-service clinical research offerings by its pharmaceutical and biotechnology clients.

Read More

Veristat Expands Its San Francisco Bay Area Operations: Opens New Office to Support Life Sciences Firms

HOLLISTON, MA – June 15, 2015Veristat, a full service Clinical Research Organization (CRO), announced today that it has opened a new office in San Bruno, California.   Located in the heart of the San Francisco Bay Area life sciences community, the office will house Veristat’s West Coast operations, and will provide a full range of clinical services to clients developing therapies in all areas of biotechnology, pharmaceuticals, diagnostics and medical devices.

Read More

Veristat Growth and Service Demand Drive Expansion: Veristat to Move Corporate Headquarters

Veristat will Move Corporate Headquarters to Southborough, MA This Summer

Read More

National Association of Professional Women Announces Cynthia Henderson, Executive Vice President of Operations at Veristat, LLC, a 2015 Professional Woman of the Year

Cynthia Henderson is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession

Garden City, NY (PRWEB) March 17, 2015

Read More

Veristat supports the battle against rare cancers by participating in the Cycle for Survival



For Immediate Release

Read More

Veristat and Molecular Templates Inc. enter into Preferred Provider Agreement for Refractory non-Hodgkin’s B-Cell Lymphoma trial

For Immediate Release

Read More

Veristat to Assist on Adaptive Enrichment Design Trial for Verastem’s Defactinib in Mesothelioma

Input Will Drive Trial Design for Lead Cancer Stem Cell-Targeting Program

 

September 10, 2013  -  Veristat, a leading, Boston-based clinical research organization today announced its advisory role on the implementation of an adaptive enrichment trial design for Verastem, Inc. (NASDAQ: VSTM).

Read More

Veristat’s Collaboration with Aegerion Contributes to FDA Approval of Juxtapid™

Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid

 

Read More

Variance Development Partners Makes a Growth Investment in Veristat

Investment Will Enable Veristat to Further Enhance its Market Leadership Position and Provide Resources for Growth

Veristat, a leading Clinical Research Organization (CRO) announced today that Variance Development Partners, a private investment group focused on contributing growth capital to small to mid-sized firms providing services to developing pharmaceutical and medical device companies, has made a growth equity investment in the company.

Read More